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Vitiligo is a  dermatological disorder characterized by destruction of melano- 
cytes and loss of pigmentation.  It affects approximately 500,000  persons in the 
United States (1). The cause of vitiligo is not known.  It has been suggested that 
immune mechanisms may be involved since vitiligo is frequently associated with 
disorders of the immune  system and the presence of autoantibodies  to various 
organs (1,  2).  In addition,  vitiligo is more common in persons and animals with 
malignant  melanoma  who  are  believed  to  have  immune  reactions  to pigment 
cells. 
To date,  however, no consistent abnormalities  in  specific immune  responses 
to  melanocytes  have  been  found  in  vitiligo.  Earlier  reports  of antibodies  to 
melanocytes in vitiligo (3-5) have either not been confirmed by other investiga- 
tors using the same technique (6) or have been found to result from other diseases 
concurrently afflicting the patients (7). 
Recently, human melanocytes have been established in tissue culture, permit- 
ting more sensitive assays of antibody to melanocytes (8). In the present studies 
we have used specific immunoprecipitation of detergent-soluble, radioiodinated 
macromolecules of normal human  melanocytes to search for antibodies to mel- 
anocytes. We have found that the majority of individuals with active vitiligo have 
antibodies to melanocyte-associated antigens. These antibodies are not found in 
patients with nonpigmentary skin diseases. 
Materials and Methods 
Sera.  Sera were collected from 120 patients. Their diagnosis is shown in Table I. 6 ! 
patients had vitiligo;  of these, 14 had common vitiligo without evidence of other autoim- 
mune disorders, 42 had vitiligo associated with various immune disorders, and 5 had in 
addition chronic mucocutaneous candidiasis (MCC).  All patients with vitiligo had active 
disease as evidenced by continued appearance of new lesions or extension of old lesions. 
59 patients without vitiligo served as controls; of these, 32 had nonpigmentary dermatosis, 
24 had malignant melanoma, and 3 had chronic MCC without vitiligo. Sera were aliquoted 
into 2-ml fractions and stored at -70°C until used. 
Cells.  Neonatal human melanocytes from three individuals were established and main- 
tained in culture as recently described by one of us (8).  The cultures were used in  the 
second or  third  passage.  >95%  of the  cells  were  melanocytes. Control ceils  included 
human  melanoma cells HM31  and HM49, established in our laboratory, and M21  and 
M3M,  kindly provided by Dr. J.  Fogh of the Sloan-Kettering Institute,  Rye, NY.  The 
* To whom reprint requests should be addressed at the N. Y.  U. School of Medicine, 560  First 
Avenue, New York, NY 10016. 
246  J. ExP. MEt). © The Rockefeller University Press • 0022-1007/83/07/0246/06  $1.00 
Volume 158  July 1983  246-251 NAUGHTON ET  AL.  BRIEF  DEFINITIVE REPORT  247 
M21  cells were pigment producing.  Normal human  keratinocytes and fibroblasts were 
established in culture as previously published (9) and used in the first to third passages. 
All melanoma cells were grown in plastic culture dishes in RPMI  1640 medium supple- 
mented with  10% fetal calf serum and 0.02  mg/ml each of gentamycin, spectinomycin, 
and penicillin. Cells were used when forming confluent cultures. 
Lactoperoxidase-catalyzed radioiodination.  Surface macromolecules on melanocytes and 
control cells were radioiodinated by the lactoperoxidase method (I0). Briefly, cells were 
collected gently  with  a  rubber policeman,  washed  three  times  with  15  ml  of ice-cold 
Hank's balanced  salt solution  (HBSS) without  calcium and  magnesium, and  the  pellet 
resuspended in  1 ml of the HBSS. 2-2.5  X 106 cells were radioiodinated with  1 mCi of 
~r'I-sodium (New England Nuclear, Boston, MA) in the presence of 0.5 mg of lactoper- 
oxidase and 0.025  ml of 0.03%  hydrogen peroxide in phosphate-buffered saline (PBS). 
Additional 0.025 ml aliquots of 0.03% hydrogen peroxide were added at 3 min intervals. 
After 10 rain the cells were washed four times with 50 ml of HBSS. Cell viability following 
radioiodination  was  90-95%  by trypan  blue exclusion.  Labeled  macromolecules were 
solubilized by lysing the cells in  1.0  ml of 0.5%  Nonidet  P-40 (NP-40) (Shell  Chemical 
Corp., Houston, TX) for 1 h at 4 °C, a procedure that solubilized >95% of the radioactivity 
associated with labeled macromolecules. Insoluble material was removed by centrifugation 
at  12,000 g for 20 rain.  Radioactivity associated with acid-insoluble radiolabeled macro- 
molecules was measured by precipitation with 10% trichloroacetic acid (TCA). 
Immunoprecipitation Assays.  Antibodies to melanocytes and control cells were measured 
by specific immunoprecipitation with protein A-Sepharose. 0.1  ml of test serum, diluted 
1:10 in PBS, pH 7.4, and 0.1  ml of radioiodinated cell lysate, diluted  1:2.5 in PBS and 
containing 8-11  X  104 TCA-insoluble cpm, were added to 0.2  ml of 0.5%  NP-40 with 
0.25% bovine serum albumin and incubated at 4 °C. After 12 h, 0.02 ml of a 1:1 suspension 
of protein A-Sepharose (Pharmacia Inc., Piscataway, NJ) in PBS was added to all tubes 
and agitated continuously at 4°C.  After 2 h, samples were centrifuged at 2,000 g for 3 
rain in a microfuge, the pellets washed four times with 0.2 ml of PBS with 0.5%  NP-40, 
and  their  radioactivity  determined.  All  assays  were  performed  in  duplicate,  and  the 
average value used. Variation between replicate samples was +1.0%. Specific binding was 
calculated by subtracting from the average cpm bound by test serum, the cpm bound by 
an equal volume of a normal human serum. The same normal serum was used as control 
in all studies. Sera were considered positive for antibodies when 2.5% or more of the acid- 
insoluble radioactivity was bound specifically. 
Pol~clcrvlamide Gel Electrophoresis (PAGE).  Immunoprecipitates generated with vitiligo 
and  normal  sera  were  examined  by  sodium  dodecyl  sulfate  (SDS)-8%  PAGE  under 
reducing conditions and radioautography as previously described (11).  Immunoprecipi- 
tates  were  solubilized  by  heating  for  3  min  at  100°C  in  buffer  containing  a  final 
concentration of 10% glycerol, 1% SDS, 2% 2-mercaptoethanol, 0. I M Tris-HCl, pH 8.0, 
and  0.01%  bromophenol  blue,  and  run  in  buffer containing  0.1%  SDS  and  1.0%  2- 
mercaptoethanol. 
lmmunofluorescence Assays.  Replicate aliquots ofmelanocyte or control cells were plated 
in microtiter plates (Lab-Tek Div., Miles Laboratories, Inc., Naperville, IL) at a density 
of 5 x  103 cells/well in 0.5  mt of culture media, and incubated at 37°C for 24 h. The 
cells were washed three times with 0.7 ml of HBSS per well, incubated with 0.5 ml of test 
serum diluted  1:10 in PBS for 30 min at 37°C, washed three times with 0.7 ml of PBS, 
and reincubated  for 30  min with fluorescein-conjugated goat anti-human  IgG (Hyland 
Diagnostics, Deerfield, IL) diluted  1:40 in PBS.  The cells were washed again three times 
with  PBS and  examined immediately with  a  Nikon  binocular  microscope (Nikon  Inc., 
Garden City, NY) equipped for immunofluorescence. 
Results 
Alltibodies to Mela~ocl,tes.  Human sera from patients with vitiligo (61  patients), 
melanoma (24), nonpigmentary diseases (32), and MCC (3) were tested by specific 
immunoprecipitation for antibodies to melanocytes. The results are presented in 
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FIGURE  1.  Incidence  of melanocyte antibodies in  sera of patients with  vitiligo,  melanoma 
nonpigmentary dermatoses, and MCC without vitiligo. 8-11  x  10  4 input TCA-insoluble cpm 
per test. 
TABLE  I 
Antigen-binding Antibodies to Melanocytes  in Vitiligo 
Percent with  Number of  antibodies* to 
Diagnosis  patients  surface antigens 
Vitiligo  61  82 
Common vitiligo  14  100 
Vitiligo  and autoimmune diseases  42  74 
Thyroiditis  18  89 
Thyroiditis and diabetes  8  61 
Hypoparathyroidism and alopecia areata  9  66 
Pernicious anemia  2  50 
Vitiligo and MCC  5  100 
Melanoma  24  12 
Nonpigmentary diseases  32  0 
MCC without vitiligo  3  0 
* Sera binding specifically  at least 2.5% of cpm associated with acid-insoluble melanocyte 
macromolecules. 
antibodies to melanocytes. This included 14 of 14 patients with common vitiligo, 
5 of 5 patients with vitiligo associated with chronic MCC, and 31  (74%) of 42 
patients  with  vitiligo  associated  with  other  immune diseases.  By contrast,  no 
antibodies to melanocytes were found in  32  patients with nonpigmentary skin 
diseases or in 3 patients with chronic MCC without vitiligo. 3 (12%) of 24 patients 
with  melanoma had antibodies  to  melanocytes, but  their  binding activity was 
much lower than that of vitiligo patients (Fig.  1). There was a linear relationship 
between the proportion  of radioactivity bound specifically and the volume of 
melanocyte antibody-positive serum used in the assay, suggesting that the assay 
provided  a  quantitative  estimate  of melanocyte antibody  level.  Five  of the 
antibody-positive sera and five of the negative sera were tested against the same 
line  of  melanocytes on  three  different  occasions.  The  results  were  similar, 
indicating that the assay was reproducible. 
Eight of the melanocyte antibody-positive vitiligo sera and four normal sera 
were tested for reactivity to melanocytes derived from three different individuals. 
All vitiligo,  but none of the normal, sera were positive against all three lines, 
indicating that the antibodies were directed to antigen(s) common to melanocytes. 
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precipitated by three vitiligo (lanes 1, 2, 3) and two normal human sera (lanes 4, 
5) is shown in Fig.  2. The vitiligo sera immunoprecipitated a labeled protein of 
~,75,000 mol wt, which was not immunoprecipitated by the normal sera. 
Reactions to Control Cells.  To study the specificity of antibodies to melanocytes, 
all sera were tested for binding activity to radioiodinated surface macromolecules 
prepared and solubilized from control cells in a manner identical to that used to 
prepare  material  from melanocytes. The results obtained with vitiligo sera are 
illustrated  in  Fig.  3.  No significant  binding  was detected to normal  allogeneic 
keratinocytes  or  fibroblasts.  Subsequently,  the  vitiligo  sera  were  found  to  be 
unreactive  against  an  additional  three  lines  of allogeneic  fibroblasts.  Several 
vitiligo sera reacted weakly to three of four melanoma lines. The three melanoma 
sera previously shown to react weakly to melanocytes were unreactive to mela- 
nomas or normal cells. Sera of patients with nonpigmentary dermatosis or chronic 
MCC without vitiligo did not react to any of the cells studied. 
Antibodies to Melanocvtes by Immunofluorescence.  To confirm that the immuno- 
precipitation assay was measuring antibodies directed to antigens on melanocytes, 
five randomly  selected antibody-positive vitiligo sera and  five negative control 
sera were tested for antibodies to melanocytes by indirect  immunofluorescence 
using unfixed cells as substrate. All vitiligo sera reacted strongly to melanocytes, 
giving  a  granular  pattern  of fluorescence.  When  appropriately  focussed,  the 
staining  could  be seen  to  involve  the  entire  surface  of the  cells.  There  was a 
correlation  between the intensity of the staining and the binding activity of the 
sera as found by specific immunoprecipitation.  By contrast,  none of the control 
sera reacted to melanocytes. Neither vitiligo or normal sera reacted to melanoma 
cells used as controls. Identical results were obtained in two similar experiments. 
Melanocyte Antibodies  in Chronic MCC.  Because prior studies have shown that 
FIGURE 2.  SDS-PAGE profile of detergent-soluble, radioiodinated macromolecules of nor- 
mal human melanocytes immunoprecipitated by sera from three patients with vitiligo (lanes 
1-3) and  two  normal  individuals (lanes  4  and  5).  A  protein  with a  tool  wt of ~75,000  is 
immunoprecipitated by all three vitiligo sera but not by the normal sera.  Lane 6  represents 
the pattern of detergent-soluble radioiodinated proteins in the melanocyte lysate. 
FIGURE  3.  Reaction of 61  vitiligo sera with radioiodinated surface macromolecules solubi- 
lized from  melanocytes, pigmented and  nonpigmented  melanoma cells, and  normal  human 
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complement-fixing antibodies to melanocytes are associated with chronic MCC 
(7), the relation of melanocyte antibodies detected by specific immunoprecipita- 
tion to chronic MCC was examined. The 120 sera tested included 8 from patients 
with  chronic  MCC.  Of these,  five had vitiligo and  three did not.  Melanocyte 
antibodies detected by specific immunoprecipitation were present in all of the 
patients with both MCC and vitiligo but in none of the MCC patients who did 
not have vitiligo. 
Discussion 
The most important finding of this study is that the majority of patients with 
vitiligo  have circulating antibodies  to  antigens of normal human  melanocytes 
that can be detected by specific immunoprecipitation and indirect immunofluo- 
rescence. These antibodies do not react to several unrelated normal human cells 
and are not found in patients with nonpigmentary diseases. 
Although the cause of vitiligo is not presently known, it is believed that immune 
mechanisms may be involved in its pathogenesis. However, repeated attempts to 
demonstrate abnormalities in humoral and/or cellular immunity in vitiligo have 
failed. Recent reports that a  few patients with vitiligo have complement-fixing 
antibodies to cytoplasmic antigens of melanocytes (4, 5) have been superceded 
by a  subsequent study of a much larger number of vitiligo patients that found 
this to be a result of chronic MCC, which was concurrently afflicting the antibody- 
positive patients (7). 
The recent development of methods to grow human melanocytes in culture 
free of contaminating cells permits the study ofhumoral immunity to melanocytes 
with  more sensitive assays.  We  have  taken  advantage  of this  opportunity  by 
studying melanocyte antibodies with a sensitive and quantitative antigen-binding 
assay  based  on  the specific immunoprecipitation of lactoperoxidase-radioiodi- 
nated  melanocyte macromolecules that  have been  solubilized  with  detergent. 
Using this approach, we found that the majority of patients with active vitiligo 
have antibodies to melanocytes. Antibodies were found in  82%  of 61  patients 
with vitiligo. The antibodies were as common in patients with common vitiligo 
(100~  of  14  patients)  as  in  the  patients  with  vitiligo  associated  with  other 
autoimmune diseases (74~ of 42) or chronic MCC (100% of 5). These antibodies 
were not  detected in  32  patients  with  nonpigmentary skin  disorders or  in  3 
patients with chronic MCC without vitiligo. They were found infrequently (12%) 
and in low titers in patients with malignant melanoma. The antibodies could also 
be detected by indirect immunofluorescence using unfixed cells as substrate. 
The antigen(s) appear to be melanocyte associated, since antibodies to it do 
not react to normal human fibroblasts or keratinocytes. The antigen(s) is common 
to me]anocytes, since positive sera reacted equally well to melanocytes obtained 
from several different individuals.  Preliminary SDS-PAGE analysis of immuno- 
precipitates  generated  with  vitiligo  sera  suggests  that  the  antigen(s)  has  an 
approximate  molecular  weight  of 75,000.  Antibodies  in  a  few  patients  with 
vitiligo reacted to some malignant melanoma cells and, conversely, some patients 
with melanoma reacted weakly to melanocytes, suggesting that one or more of 
the  antigen(s)  may  be  expressed,  though  in  smaller  amounts,  on  malignant 
melanoma cells.  The nature of the antigen defined by vitiligo sera remains to be 
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The presence of antibodies of melanocytes in the vast majority of patients with 
active common vitiligo provides direct evidence that alterations  in  specific im- 
munity to pigment cells occurs in this disease. The finding suggests, but does not 
prove, that vitiligo is mediated by antibodies to melanocyte-associated antigen(s). 
Summary 
Most  patients  with active  vitiligo (82%  of 61)  have antibodies  to antigens  of 
normal human melanocytes that can be detected by specific immunoprecipitation 
of radioiodinated, detergent-soluble, melanocyte macromolecules. Such antibod- 
ies  were  present  in  only  12~  of patients  with  melanoma  and  in  none  of  35 
patients  with  nonpigmentary skin  diseases.  The  antibodies  were directed  to a 
common antigen(s)  on  melanocytes that  was not present on normal  fibroblasts 
or  keratinocytes.  These  observations  suggest  that  vitiligo  is  an  autoimmune 
disease mediated by antibodies to melanocyte-associated antigen(s). 
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